The government’s decision to grant a compulsory licence for the manufacture of an important anti-cancer drug should be the first step towards making available essential drugs at little or no direct cost.
Read more: The Hindu, March 14, 2012
-
Recent Posts
- Civil Society Letter regarding non-compliance of private hospitals and lack of enforcement of the Delhi treatment rate caps for COVID-19 treatment
- Need for Patient-Oriented Comprehensive Regulation of Medical Devices
- AIDAN’s statement on negotiations on medical devices in the context of US-India trade deal
- Anti-Cancer Drugs: Caps on Trade Margins will still leave most patients poorer
- AIDAN’s response to the DTAB sub-committee’s recommendations on FDCs
- ACTA AIDAN Annual Meet Book release Clinical Trials Conflict of Interest draft policy Drug Pricing Drug Promotion Essential Drugs essential medicines EU FDA Generic drug Global Health Health India India-EU FTA IPR Letter Machines Marketing Medical Medical Council of India Medicine Medicine pricing Medicines National Pharmaceuticals Pricing Policy Patent Pharma Industry Pharma Policy Photo PIL Polio Price Control Profit Rational Drugs Reports Sec 3 (d) Supreme Court Supreme Court of India TRIPS Vaccine WHO WTO
Blog Stats
- 127,815 hits
-
Join 222 other followers
All India Drug Action Network (AIDAN) 